Dibekacin Sulfate is the sulfate salt form of Dibekacin, an aminoglycoside antibiotic. It is a semisynthetic 3',4'-dideoxy derivative of kanamycin B developed by Hamao Umezawa and others by Meiji Seika. It has broad-spectrum antibacterial activity and can be used in susceptibility testing. It can be used in combination with sulbenicillin to enhance its bactericial activity.
Dibekacin is soluble in water and DMSO.
| Mechanism of Action |
Aminoglycosides target the 30S ribosomal subunit resulting in an inability to read mRNA ultimately producing a faulty or nonexistent protein. Its primary mechanism of action involves the irreversible binding to the 30S subunit of the bacterial ribosome . This binding disrupts the initiation complex formation and causes misreading of mRNA, leading to the production of faulty proteins and ultimately bacterial cell death |
| Spectrum | Dibekacin has broad-spectrum antibacterial activity, particularly against Gram-negative bacteria, including resistant strains. |
| Microbiology Applications |
Dibekacin in combination with Sulbenicillin caused bacilli elongation of bacilli and severe destruction of the inner and outer membranes of the bacterial cell wall. These morphological changes occurred even when the concentration of the individual compound was lower than its minimum inhibitory concentration (MIC). Their effects on the cell wall were complementary and synergistic (Aonuma et al, 1987) Dibekacin is commonly used in clinical in vitro microbiological antimicrobial susceptibility testing methods (broth microdilution, agar dilution, and disk diffusion ie Kirby-Bauer methods against microbial isolates. |
| Molecular Formula |
C18H39N5O12S |
| References |
Aonuma S, Ariji F, Oizumi K, Konno K. Electron microscopy of Pseudomonas aeruginosa treated with sulbenicillin and dibekacin. Tohoku J Exp Med. 1987 Jun;152(2):119-28. doi: 10.1620/tjem.152.119. PMID: 3114912. Umezawa H, Umezawa S, Tsuchiya T, Okazaki Y (1971) 3',4'-dideoxy-kanamycin B active against kanamycin-resistant Escherichia coli and Pseudomonas aeruginosa. J Antibiot (Tokyo). Jul;24(7):485-487 PMID 4998037 |
